By: IPP Bureau
Last updated : June 18, 2026 2:58 pm
Industry veteran with over two decades of experience to lead expansion across India, South Asia, Southeast Asia, and other high-growth healthcare markets
Brinton Pharmaceuticals Ltd. has appointed Sathya Narayanan as Chief Executive Officer – India Cluster & JPAC (Japan Asia Pacific Cluster), reinforcing the company's leadership team as it accelerates its global growth ambitions.
The appointment underscores Brinton’s strategic focus on expanding its presence across India, South Asia, Southeast Asia, and other rapidly growing healthcare markets. In his new role, Narayanan will spearhead business growth initiatives, strengthen market positioning, and drive the company’s regional expansion efforts.
A seasoned pharmaceutical executive, Narayanan brings more than 20 years of experience spanning pharmaceuticals and dermatology. Throughout his career, he has demonstrated expertise in building high-performing teams, driving sustainable business growth, and enhancing organizational competitiveness.
Prior to joining Brinton, he served as Managing Director, Galderma South Asia/Emcutix, where he played a key role in strengthening the company’s market presence in the region.
Commenting on the appointment, Rahulkumar Darda, Chairman & Managing Director, Brinton Pharmaceuticals, said that India and neighbouring markets remain central to the company’s long-term growth strategy. He expressed confidence that Narayanan’s extensive industry experience and leadership capabilities would help guide Brinton through its next phase of expansion.
Sharing his views on the new role, Narayanan said Brinton’s strong foundation in innovation, scientific excellence, and patient-centric healthcare solutions presents a significant opportunity to broaden access to quality healthcare and introduce differentiated therapies across the region.